New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:48 EDTKPTIKaryopharm initiates study of Selinexor in older AML patients
Karyopharm Therapeutics announced the initiation of its Phase 2 study of Selinexor in patients 60 years of age or older with relapsed or refractory acute myeloid leukemia, or AML, who are ineligible for intensive chemotherapy and/or transplantation. This Selinexor in Older Patients with Relapsed/Refractory AML, or SOPRA, study is a randomized trial of Selinexor, the company's novel oral Selective Inhibitor of Nuclear Export compound, versus physician's choice, and will be conducted at approximately 40 sites worldwide including sites in the United States, Canada, Europe and Israel.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 13, 2015
08:43 EDTKPTIKaryopharm granted U.S. composition-of-matter patent for selinexor
Karyopharm Therapeutics announced the issuance of U.S. Patent No. 8,999,996 entitled "Hydrazide Containing Nuclear Transport Modulators and Uses Thereof." This patent, which will expire in 2032 absent any patent term extensions, covers the composition-of-matter of Karyopharm's lead product candidate, selinexor, a first-in-class, oral SINE compound, as well as certain other compositions and related methods. Selinexor is being evaluated in multiple registration-directed and other later stage trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use